Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Famciclovir - Novartis

Drug Profile

Famciclovir - Novartis

Alternative Names: AK-120; BRL-42810; Famvir

Latest Information Update: 23 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Asahi Kasei Pharma Corp; Astellas Pharma; GlaxoSmithKline; Maruho; Novartis; Solvay
  • Class Antivirals; Nucleosides; Purines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Herpes simplex virus infections; Herpes zoster; Herpesvirus infections
  • No development reported Herpes labialis
  • Discontinued Epstein-Barr virus infections; Hepatitis B

Most Recent Events

  • 31 Oct 2018 Maruho completes a phase III trial for Herpes simplex virus infections (Recurrent) in Japan (PO) (JapicCTI-163223)
  • 01 Mar 2016 Maruho initiates a phase III trial for Herpes simplex virus infections in Japan (PO) (JapicCTI-163223)
  • 21 Feb 2013 Registered for Herpes simplex virus infections in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top